Expanding the customer base through overseas sales, web marketing and ambassador shops
First written in FY2016. 11 of 17 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2023-Q2.
The whole theme swung hardest in 2024: 3 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- FY2023-Q2AdvancedAnnual report
「Second-quarter net sales increased to ¥75 million, or 110.7% of the year-earlier period, owing to higher sales from OEM production of Hanabiratake products.」
Sales of hanafuki products through OEM arrangements increased, contributing to higher revenue in the healthcare business. - FY2022AdvancedAnnual report
「The publication in the academic journal Applied Pharmacology of a paper titled “Evaluation of the Efficacy and Safety of Hanabiratake in Relieving Unpleasant Symptoms of Menopause in Women” also increased inquiries about “IT Hanabiratake” from major health-food manufacturers, and the company is preparing for further sales growth.」
The increase in inquiries from major health food manufacturers is described as a new sales opportunity for hanafuki products. - FY2022-Q3AdvancedAnnual report
「Inquiries about “IT Hanabiratake” from major health-food manufacturers have increased, and the company is preparing for further sales growth.」
The increase in inquiries from major health-food manufacturers has advanced sales and marketing activities aimed at expanding sales of Hanabiratake products. - FY2021RestatedAnnual report
「We will establish our position as a Hanabiratake manufacturer by leveraging alliances with major companies and a women’s healthcare network, distributing products through channels that more readily reach general consumers and using this to expand sales.」
The company continues to pursue sales expansion measures using alliances with major companies, a women’s healthcare network and channels serving general consumers. - FY2020AdvancedAnnual report
「We will establish our position as a Hanabiratake manufacturer by leveraging alliances with major companies and a women’s healthcare network, distributing products through channels that more readily reach general consumers and using this to expand sales.」
The company set out specific sales and awareness-building measures using alliances with major companies and a women’s healthcare network, together with plans to expand distribution through channels serving general consumers. - FY2020-Q2SoftenedAnnual report
「Following the sale of Intertrade Healthcare’s mail-order business in order to focus on developing the business as an “IT Hanabiratake” manufacturer, second-quarter net sales were ¥97 million, or 66.0% of the year-earlier period.」
The company changed from expanding customers and sales channels, including the traditional mail-order business, to selling the mail-order business and concentrating management resources on the IT Hanabiratake manufacturing business. - FY2019AdvancedAnnual report
「Sales of products related to “IT maitake” produced by the company and possessing silent estrogen activity, including “EstroRich,” a supplement sold exclusively by 株式会社大木, a major pharmaceutical wholesaler, as well as OEM services and raw-material sales, remained firm. Revenue reached ¥293 million, or 114.0% of the previous fiscal year's level.」
Sales expansion through the exclusive-product channel of a major pharmaceutical wholesaler, together with OEM products and raw material sales, continued, bringing Healthcare net sales to ¥293 million. - FY2019-Q3RestatedAnnual report
「Sales of products related to “IT Hanabiratake” with silent estrogen activity produced by the company, including 株式会社大木’s exclusive-product supplement “EstroRich,” as well as OEM products and raw materials, remained solid.」
The company continues to expand sales through 株式会社大木’s exclusive-product channel, OEM products and raw material sales. - FY2019-Q2RestatedAnnual report
「Sales of products related to “IT Hanabiratake” with silent estrogen activity produced by the company, including 株式会社大木’s exclusive-product supplement “EstroRich,” as well as OEM products and raw materials, remained solid.」
The company continues to expand sales through 株式会社大木’s exclusive-product channel, OEM products and raw material sales. - FY2019-Q1AdvancedAnnual report
「Sales of “EstroRich,” a supplement containing “IT Hanabiratake” produced by the company, as an exclusive product of 株式会社大木, a major pharmaceutical wholesaler, remained strong. The company also sold supplements for foreign consumers.」
In addition to sales through 株式会社大木’s exclusive-product channel, the company continued selling supplements for foreign consumers and reported results from sales growth. - FY2018RestatedAnnual report
「The company actively sold the new product “IT Hanabiratake Furikake,” launched in January 2018, at department stores and other outlets and distributed it through channels that readily reach general consumers. It also began launching “EstroRich,” a supplement containing IT Hanabiratake, as an exclusive product of 株式会社大木, a major pharmaceutical wholesaler.」
The company continues to expand sales through consumer-facing channels, such as department stores, and exclusive-product channels operated by a major pharmaceutical wholesaler. - FY2018-Q3AdvancedAnnual report
「The company actively sold the new product “IT Hanabiratake Furikake,” launched in January 2018, at department stores and other outlets and distributed it through channels that readily reach general consumers. It also began launching “EstroRich,” a supplement containing IT Hanabiratake, as an exclusive product of 株式会社大木, a major pharmaceutical wholesaler.」
In addition to sales channels serving general consumers, such as department stores, the company developed an exclusive-product channel through a major pharmaceutical wholesaler. - FY2018-Q2AdvancedAnnual report
「The new product “IT Hanabiratake Furikake,” launched in January 2018, was sold at department stores and other outlets and distributed through channels that readily reach general consumers.」
The new product was distributed through department stores and other channels that readily reach general consumers, giving concrete form to the expansion of sales channels. - FY2018-Q1AdvancedAnnual report
「From the second quarter onward, business discussions with major department stores also progressed. We will expand sales by distributing maitake products through channels that make them more accessible to general consumers and through various initiatives, including OEM supply to major companies.」
The company has identified progress in negotiations with major department stores, sales channels for general consumers and OEM supply to major companies as new initiatives to expand sales. - FY2017AdvancedAnnual report
「We will expand sales by distributing products through channels that more readily reach general consumers.」
The company has indicated a policy of expanding sales through distribution channels that readily reach general consumers, alongside its adoption by Laox and other outlets. - FY2017-Q3AdvancedAnnual report
「Our cosmetics were adopted for Laox株式会社’s cosmetics and beauty specialty area, Japan Cosmetic Lounge, strengthening sales targeting inbound visitors.」
The company is specifically strengthening sales targeting inbound visitors by having its cosmetics adopted by sales outlets. - FY2016First statedAnnual report
「On the sales front, we aim to increase active customers through sales activities targeting organizations where demand for healthcare products is expected, stronger sales efforts in overseas markets, web marketing and ambassador shops.」
The company lists sales to organizations where demand is expected, overseas sales, web marketing and ambassador shops as sales initiatives.